Overview

A Study of Lebrikizumab in Combination With Topical Corticosteroids in Participants Having Atopic Dermatitis (AD) That Are Not Adequately Controlled or Non-eligible for Cyclosporine

Status:
Not yet recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.

Phase:

Phase 3

Details

Lead Sponsor:

Almirall, S.A.

Treatments:

Antibodies, Monoclonal